Patent intelligence · US
US 7595326
Synthesis of novel tubulin polymerization inhibitors: benzoylphenylurea (BPU) sulfur analogs
Synthesis of novel tubulin polymerization inhibitors: benzoylphenylurea (BPU) sulfur analogs
Patent details — US 7595326
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 29, 2009
- Expiration
- Sep 24, 2029
- Applicant
- Champions Biotechnology, Inc
- Claims
- 12
- CPC classes
- A61K, A61K31/38, A61K31/404, A61K31/4152
Quick answer
US 7595326 (Synthesis of novel tubulin polymerization inhibitors: benzoylphenylurea (BPU) sulfur analogs) is held by Champions Biotechnology, Inc. Status: granted. Granted Sep 29, 2009. Expires Sep 24, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Champions Biotechnology, Inc
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/38, A61K31/404, A61K31/4152, A61K31/427, A61K31/428
Frequently asked questions
What is US patent 7595326?
US 7595326 (Synthesis of novel tubulin polymerization inhibitors: benzoylphenylurea (BPU) sulfur analogs) is held by Champions Biotechnology, Inc. Status: granted. Granted Sep 29, 2009. Expires Sep 24, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7595326?
Champions Biotechnology, Inc is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 7595326 expire?
Our index shows an expiration date of Sep 24, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.